Copenhagen, July 29 — In a dramatic turn that evoked memories of the 2008 financial crisis, Novo Nordisk lost DKK 465 billion in market value in a single trading session. The company’s 23% share price collapse marks the worst day in its 101-year history, eclipsing its prior record (-20% in December 2024) and wiping out the equivalent of Denmark’s largest bank, Danske Bank.
1. What Triggered the Rout?
a. CagriSema’s “Near-Miss”
Investors had high hopes for CagriSema, a once-weekly injectable combining semaglutide and cagrilintide. The drug was pitched as Novo’s answer to Eli Lilly’s Zepbound. But updated Phase III data released Monday night showed just 15.7% weight loss after 68 weeks, falling short of the 22–25% whisper numbers and barely outperforming Wegovy’s 15%. Analysts quickly slashed peak sales estimates from USD 25 billion to USD 8 billion.
b. U.S. Policy Whiplash
Earlier the same day, the Trump administration confirmed semaglutide’s inclusion in Medicare’s first wave of price negotiations (effective 2027) and floated a 20% tariff on European-made biologics. Novo, which derives 60% of GLP-1 revenue from the U.S. but manufactures mostly in Denmark, faces pressure on both price and cost structure.
c. Market Share Erosion
New prescription data showed Zepbound surpassing Wegovy in weekly U.S. scripts for the first time. The symbolic turning point triggered algorithmic trading and momentum-based sell-offs, deepening the collapse.
2. By the Numbers
| Metric | 28 July Close | 29 July Close | Change |
| Share Price (DKK) | 578.20 | 445.20 | ‑23% |
| Market Cap (DKK bn) | 2,023 | 1,558 | ‑465 |
| Forward P/E (2026e) | 19.4× | 14.9× | — |
| EV / 2026e EBITDA | 13.8× | 10.6× | — |
At its June 2024 peak, Novo’s market value (DKK 2.9 trillion) exceeded Denmark’s GDP. It now ranks third among European firms, behind LVMH and SAP.
3. Leadership Shakeup
In response, the board announced that CEO Lars Fruergaard Jørgensen will step down “by mutual agreement” once a successor is appointed. Former CEO and current Novo Nordisk Foundation chair Lars Rebien Sørensen will return as a board observer to “ensure strategic continuity.”
4. Pipeline Damage Control
Novo’s leadership moved quickly to shore up confidence:
- Amycretin (oral GLP-1 + amylin): Phase II data due Q4 2025.
- Once-weekly insulin IcoSema remains on track for 2026 filing.
- Wegovy U.S. cash price cut by 50% rolled out last week to defend market share.
Still, analysts warn that patent cliff risk is growing. Key U.S. semaglutide patents expire in 2028, and biosimilars could arrive by 2029 if granted FDA interchangeability.
5. Wall Street Reaction
| Bank | New TP (DKK) | Rating | Key Insight |
| JPMorgan | 520 | Neutral | “CagriSema delay removes 8% EPS CAGR” |
| Morgan Stanley | 680 | Overweight | “Buy the dip; obesity TAM still >USD 200 bn” |
| Danske Bank | 480 | Hold | “Policy overhang too large; prefer Lilly” |
Consensus 12-month target has dropped from DKK 720 to DKK 565, implying 27% upside—down from 57% a week ago.
6. Fallout for Denmark Inc.
Novo Nordisk represents approximately 45% of the OMXC25 index and 2% of Danish GDP through taxes and dividends. Major pension funds PFA and ATP have flagged “temporary but material” impacts to 2025 solvency ratios. In response, the Danish Business Authority convened an emergency meeting today to discuss economic contingency planning.
7. What’s Next?
For long-term investors, the structural bull case remains: a USD 150+ billion obesity market growing at 15% CAGR, with Novo retaining global manufacturing leadership.
But for traders, the road ahead is bumpy. Key catalysts:
- Q2 earnings call on 7 August, where 2025 guidance may be cut again.
- FDA feedback on CagriSema NDA timeline, expected later this quarter.
As one Copenhagen-based fund manager put it:
“Today’s move prices in a 50% chance Novo becomes the next Nokia. The market tends to overreact to pipeline shocks—this could be a generational entry point, but only if you can stomach the next 12–18 months of headline risk.”
© Nordic Business Journal 2025. All rights reserved.